替格瑞洛与普拉格雷在STEMI直接PCI患者中的比较
该研究为ISAR REACT-5试验的预设亚组分析,纳入1653例接受直接PCI的ST段抬高型心肌梗死患者,随机接受替格瑞洛或普拉格雷。1年主要终点(死亡、心肌梗死或卒中)两组无显著差异,但替格瑞洛组心肌梗死发生率显著高于普拉格雷组,BARC 3~5型出血无显著差异。
要点
- 替格瑞洛与普拉格雷1年主要复合终点无显著差异
- 替格瑞洛组1年心肌梗死风险显著高于普拉格雷组
- 两组BARC 3~5型出血发生率无显著差异
核心结论
- 在直接PCI的STEMI患者中,替格瑞洛与普拉格雷的主要终点无显著差异,但替格瑞洛与再发心肌梗死风险显著增加相关。
研究设计与样本
- ISAR REACT-5试验的预设亚组分析,纳入1653例接受直接PCI的ST段抬高型心肌梗死患者,随机接受替格瑞洛或普拉格雷。
主要发现
- 主要终点(1年死亡、心肌梗死或卒中)替格瑞洛组83例(10.1%)、普拉格雷组64例(7.9%),HR 1.31(95%CI 0.95-1.82),P=0.10。
- 1年心肌梗死发生率替格瑞洛组5.3%、普拉格雷组2.8%,HR 1.95(95%CI 1.18-3.23),P=0.010。
- 1年全因死亡(4.9% vs 4.7%,P=0.83)、卒中(1.3% vs 1.0%,P=0.46)、明确支架内血栓(1.8% vs 1.0%,P=0.15)均无显著差异。
- BARC 3~5型出血替格瑞洛组46例(6.1%)、普拉格雷组39例(5.1%),HR 1.22(95%CI 0.80-1.87),P=0.36。
临床怎么用
- 对于接受直接PCI的STEMI患者,选择替格瑞洛或普拉格雷时需权衡再发心肌梗死风险,替格瑞洛组心肌梗死风险较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data on the comparative efficacy and safety of ticagrelor versus prasugrel in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention are limited. We assessed the efficacy and safety of ticagrelor versus prasugrel in a head-to-head comparison in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. METHODS: In this prespecified subgroup analysis, we included 1653 patients with ST-segment-elevation myocardial infarction randomized to receive ticagrelor or prasugrel in the setting of the ISAR REACT-5 trial (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5). The primary end point was the incidence of death, myocardial infarction, or stroke at 1 year after randomization. The secondary end point was the incidence of bleeding defined as BARC (Bleeding Academic Research Consortium) type 3 to 5 bleeding at 1 year after randomization. RESULTS: The primary end point occurred in 83 patients (10.1%) in the ticagrelor group and in 64 patients (7.9%) in the prasugrel group (hazard ratio, 1.31 [95% CI, 0.95-1.82]; P=0.10). One-year incidence of all-cause death (4.9% versus 4.7%; P=0.83), stroke (1.3% versus 1.0%; P=0.46), and definite stent thrombosis (1.8% versus 1.0%; P=0.15) did not differ significantly in patients assigned to ticagrelor or prasugrel. One-year incidence of myocardial infarction (5.3% versus 2.8%; hazard ratio, 1.95 [95% CI, 1.18-3.23]; P=0.010) was higher with ticagrelor than with prasugrel. BARC type 3 to 5 bleeding occurred in 46 patients (6.1%) in the ticagrelor group and in 39 patients (5.1%) in the prasugrel group (hazard ratio, 1.22 [95% CI, 0.80-1.87]; P=0.36). CONCLUSIONS: In patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention, there was no significant difference in the primary end point between prasugrel and ticagrelor. Ticagrelor was associated with a significant increase in the risk for recurrent myocardial infarction. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01944800.
引用
- Aytekin A, Ndrepepa G, Neumann FJ, et al. Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation. 2020. PMID: 33115278. doi:10.1161/CIRCULATIONAHA.120.050244
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。